Saturday, June 28, 2025

Phylogenetic and #Mutation #Analysis of #Hemagglutinin Gene from Highly Pathogenic Avian #Influenza Virus #H5 Clade 2.3.4.4b in South #America

Abstract

The Highly Pathogenic Avian Influenza Virus (HPAIV) H5 clade 2.3.4.4b has caused severe outbreaks in domestic and wild birds worldwide since its emergence in 2014, and especially since 2020, with outbreaks in Europe and North America. The introduction of the virus into South America was reported for the first time in Colombia in October 2022, followed by outbreaks in other South American countries affecting poultry, wild birds, mammals, and humans. In this study, a phylogenetic and mutation analysis of the hemagglutinin (HA) gene of HPAIV H5N1 2.3.4.4b viruses isolated in South America was performed to analyze its evolution and its transmission and zoonotic potential. The analysis shows an increase in the viral effective population size between April and June 2022, which was followed by multiple outbreaks of HPAIV H5N1 clade 2.3.4.4b in South America. Moreover, the virus variants evolved from a recent common ancestor estimated to have existed in June 2017. The mean rate of evolution of the HA gene was 6.95 × 10−3 substitutions per site per year, and the sequence analysis of HA identified a mutation (D171N) located at antibody binding sites and viral oligomerization interfaces, with implications for immune response evasion and new host species infection. Additionally, viral strains from South America share the substitutions L104M, T156A, P181S, and V210A, compared to the vaccine strain A/chicken/Ghana/AVL763/2021. Understanding the dynamics of viral evolution and transmission is essential for effective prevention strategies to mitigate future outbreaks.

Source: Viruses, https://www.mdpi.com/1999-4915/17/7/924

____

History of Mass Transportation: The FS Aln 442 Diesel Multiple-Unit


Di Giorgio Stagni - http://www.stagniweb.it/foto6.asp?File=tee448&righe=1&inizio=45&InizioI=1&RigheI=100&Col=5, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=96379237

Source: Wikipedia, https://it.wikipedia.org/wiki/Automotrici_FS_ALn_442-448

____

#Coronavirus Disease Research #References (by AMEDEO, June 28 '25)

 


    Antiviral Res

  1. HUSSAIN S, Meijer A, Govorkova EA, Dapat C, et al
    Global update on the susceptibilities of influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2020-2023.
    Antiviral Res. 2025 Jun 24:106217. doi: 10.1016/j.antiviral.2025.106217.
    PubMed         Abstract available


    Clin Infect Dis

  2. HARUN MGD, Sumon SA, Anwar MMU, Mohona TM, et al
    Infection Prevention and Control Knowledge, Attitudes, and Practices of Healthcare Workers in Tertiary Care Hospitals in Bangladesh During Coronavirus Disease 2019: A Multicenter Cross-sectional Survey.
    Clin Infect Dis. 2025 Jun 25:ciaf246. doi: 10.1093.
    PubMed         Abstract available

  3. DUONG KS, Henry SS, Duong TQ
    SARS-CoV-2 infection increases long-term risk of pneumonia in an urban population: an observational cohort study up to 46 months post-infection.
    Clin Infect Dis. 2025 Jun 25:ciaf345. doi: 10.1093.
    PubMed         Abstract available

  4. OPENSHAW JJ, Chen J, Rodriguez R, Gottlieb M, et al
    The Effect of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection on Long-Term Symptoms in the Innovative Support for Patients With SARS-CoV-2 Infections Registry (INSPIRE).
    Clin Infect Dis. 2025 Jun 18:ciaf225. doi: 10.1093.
    PubMed         Abstract available


    Emerg Infect Dis

  5. TARBUCK NN, Garushyants SK, McBride DS, Dennis PM, et al
    Persistence of SARS-CoV-2 Alpha Variant in White-Tailed Deer, Ohio, USA.
    Emerg Infect Dis. 2025;31:1319-1329.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  6. WHITELEY TD, Stimson J, Brown CS, Robotham JV, et al
    Modeling the impact of health care worker masking to reduce nosocomial SARS-CoV-2 transmission under varying adherence, prevalence, and transmission settings.
    Infect Control Hosp Epidemiol. 2025 Jun 27:1-7. doi: 10.1017/ice.2025.
    PubMed         Abstract available


    Int J Infect Dis

  7. CHAPMAN A, Barouch DH, Lip GYH, Pliakas T, et al
    Risk of severe outcomes from COVID-19 in comorbid populations in the Omicron era: a systematic review and meta-analysis.
    Int J Infect Dis. 2025 Jun 24:107958. doi: 10.1016/j.ijid.2025.107958.
    PubMed         Abstract available

  8. PAUL E, Brown GW, Dechamps M, Kalk A, et al
    Corrigendum to "COVID-19: an 'extraterrestrial' disease?", [International Journal of Infectious Diseases, Volume 110, 155-159, September 2021].
    Int J Infect Dis. 2025;158:107951.
    PubMed        

  9. TEODORO LI, Ovsyannikova IG, Grill DE, Poland GA, et al
    Seroprevalence of RSV Antibodies in a Contemporary (2022 - 2023) Cohort of Adults.
    Int J Infect Dis. 2025 Jun 21:107964. doi: 10.1016/j.ijid.2025.107964.
    PubMed         Abstract available

  10. JOSEPH JT, Grau-Sepulveda M, Griffith BC, Lufes N, et al
    Evaluating the introduction of COVID-19 oral antivirals through a test and treat program: outcomes from a cohort study in four African countries.
    Int J Infect Dis. 2025 Jun 19:107956. doi: 10.1016/j.ijid.2025.107956.
    PubMed         Abstract available

  11. TSUCHIHASHI Y, Tamura K, Matsumoto K, Mitsushima S, et al
    Comparative analysis of streptococcal toxic shock syndrome caused by three beta-hemolytic streptococcal species in Japan.
    Int J Infect Dis. 2025 Jun 18:107962. doi: 10.1016/j.ijid.2025.107962.
    PubMed         Abstract available

  12. ESTILL J, Belayneh EG, Beale S, Keiser O, et al
    Estimation of the number of people affected by post COVID-19 condition in Switzerland in 2023: A mathematical model.
    Int J Infect Dis. 2025 Jun 18:107963. doi: 10.1016/j.ijid.2025.107963.
    PubMed         Abstract available


    J Med Virol

  13. SANCHEZ-SIMARRO A, Carretero D, Grau B, Martinez-Perez M, et al
    Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals.
    J Med Virol. 2025;97:e70463.
    PubMed         Abstract available

  14. WANG Y, Sun H, Liu Y, Song Y, et al
    TMEM106B Supports Viral Entry and Syncytia Formation Mediated by the Spike Proteins From Omicron BA.2.86 and JN.1.
    J Med Virol. 2025;97:e70439.
    PubMed         Abstract available

  15. BARY F, Karunananda MV, Jeewandara C, Danasekara S, et al
    Changes in Population Immunity to Omicron SARS-CoV-2 Variants and Selected Sarbecoviruses From 2020 to 2023 in Urban Colombo, Sri Lanka.
    J Med Virol. 2025;97:e70462.
    PubMed         Abstract available


    JAMA

  16. GRUNEBAUM A, Chervenak FA
    Professional Responsibility for COVID-19 Vaccination in Pregnancy.
    JAMA. 2025 Jun 25. doi: 10.1001/jama.2025.11328.
    PubMed        


    Lancet


  17. Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Jun 24:S0140-6736(25)01037-2. doi: 10.1016/S0140-6736(25)01037.
    PubMed         Abstract available

  18. PAIL O, Lin MJ, Anagnostou T, Brown BD, et al
    Cancer vaccines and the future of immunotherapy.
    Lancet. 2025 Jun 17:S0140-6736(25)00553-7. doi: 10.1016/S0140-6736(25)00553.
    PubMed         Abstract available


    Lancet Infect Dis

  19. LIU JW, Lai CC, Hsueh PR
    Resurgence of human metapneumovirus in the post-COVID-19 era: pathogenesis, epidemiological shifts, clinical impact, and future challenges.
    Lancet Infect Dis. 2025 Jun 20:S1473-3099(25)00240.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  20. DIAZ MH, Hersh AL, Olson J, Shah SS, et al
    Mycoplasma pneumoniae Infections in Hospitalized Children - United States, 2018-2024.
    MMWR Morb Mortal Wkly Rep. 2025;74:394-400.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, June 28 '25)

 


    Antimicrob Agents Chemother

  1. MENG X, Zhang C, Wang X, Shi J, et al
    A branched peptide targets virus and host to block influenza virus and rhinovirus entry.
    Antimicrob Agents Chemother. 2025 Jun 25:e0002425. doi: 10.1128/aac.00024.
    PubMed         Abstract available


    Antiviral Res

  2. HUSSAIN S, Meijer A, Govorkova EA, Dapat C, et al
    Global update on the susceptibilities of influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2020-2023.
    Antiviral Res. 2025 Jun 24:106217. doi: 10.1016/j.antiviral.2025.106217.
    PubMed         Abstract available


    Biochemistry

  3. PANKRATOVA Y, Hong M
    Side Chain Structures of the Proton-Selective Histidine and Gating Tryptophan in Influenza BM2 Reveal Both Conservation and Variation of the Proton Conduction Mechanism.
    Biochemistry. 2025 Jun 24. doi: 10.1021/acs.biochem.5c00242.
    PubMed         Abstract available


    Cell

  4. DHENNI R, Hoppe AC, Reynaldi A, Kyaw W, et al
    Macrophages direct location-dependent recall of B cell memory to vaccination.
    Cell. 2025;188:3477-3496.
    PubMed         Abstract available


    Epidemiol Infect

  5. COLEMAN BL, Robertson NM, Harrison RA, Valiquette L, et al
    Risk factors for infection with SARS-CoV-2 in a cohort of Canadian healthcare workers: 2020-2023.
    Epidemiol Infect. 2025;153:e72.
    PubMed         Abstract available


    J Infect

  6. RIVERA-IZQUIERDO M, Verdejo-Ianez A, Morales-Portillo A, Gonzalez-Alcaide M, et al
    High-dose versus standard-dose influenza vaccine for immunocompromised patients: A systematic review and meta-analysis of randomised clinical trials.
    J Infect. 2025;91:106538.
    PubMed         Abstract available

  7. WANG J, Guo S, Zhao J, Sun T, et al
    Host lncRNA assists the nuclear import of influenza A virus protein PB2 in a species-specific manner.
    J Infect. 2025;91:106540.
    PubMed         Abstract available

  8. YANG J, Chen X, Li X, Zhang Y, et al
    Global spread of H3 subtype avian influenza viruses with an accelerated evolution after interspecies transmission.
    J Infect. 2025 Jun 20:106542. doi: 10.1016/j.jinf.2025.106542.
    PubMed         Abstract available


    J Infect Dis

  9. GUILFOYLE K, Mirolo M, de Waal L, van Amerongen G, et al
    Highly Pathogenic Avian Influenza Virus A/H5N1 subclade 2.3.4.4 b isolated from a European grey seal (Halichoerus grypus) is highly virulent in ferrets.
    J Infect Dis. 2025 Jun 28:jiaf348. doi: 10.1093.
    PubMed         Abstract available

  10. LU Y, Allen JD, Ross TM, Cowling B, et al
    Evaluating the Breadth and Reliability of Influenza Vaccine Protection Indicators: a Secondary Analysis of an Animal Challenge Trial.
    J Infect Dis. 2025 Jun 20:jiaf331. doi: 10.1093.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  11. DIAZ MH, Hersh AL, Olson J, Shah SS, et al
    Mycoplasma pneumoniae Infections in Hospitalized Children - United States, 2018-2024.
    MMWR Morb Mortal Wkly Rep. 2025;74:394-400.
    PubMed         Abstract available


    PLoS Biol

  12. YIN X, Pu Y, Yuan S, Pache L, et al
    Global siRNA screen identifies human host factors critical for SARS-CoV-2 replication and late stages of infection.
    PLoS Biol. 2025;23:e3002738.
    PubMed         Abstract available


    PLoS Comput Biol

  13. GAZEAU ST, Deng X, Brunet-Ratnasingham E, Kaufmann DE, et al
    Using virtual patient cohorts to uncover immune response differences in cancer and immunosuppressed COVID-19 patients.
    PLoS Comput Biol. 2025;21:e1013170.
    PubMed         Abstract available

  14. VOUTOURI C, Munn LL, Stylianopoulos T, Jain RK, et al
    Biomarkers of mRNA vaccine efficacy derived from mechanistic modeling of tumor-immune interactions.
    PLoS Comput Biol. 2025;21:e1013163.
    PubMed         Abstract available

  15. DEICHMANN J, Barda N, Canetti M, Peretz Y, et al
    Predicting antibody kinetics and duration of protection against SARS-CoV-2 following vaccination from sparse serological data.
    PLoS Comput Biol. 2025;21:e1013192.
    PubMed         Abstract available


    PLoS One

  16. PITOL AK, Venkatesan S, Richards S, Hoptroff M, et al
    SARS-CoV-2 survival on skin and its transfer from contaminated surfaces.
    PLoS One. 2025;20:e0325235.
    PubMed         Abstract available

  17. FISH LE, Roberts SC, Bennett TD, Carlson NE, et al
    Experiences of recently diagnosed urban COVID-19 outpatients: A survey on patient worries, provider-patient interactions, and neutralizing monoclonal antibody treatment.
    PLoS One. 2025;20:e0325991.
    PubMed         Abstract available

  18. RUSSELL S, Munro K, Foulkes S, Broad J, et al
    Adapting COVID-19 research infrastructure to capture influenza and RSV alongside SARS-CoV-2 in UK healthcare workers winter 2022/23: Evaluation of the SIREN Winter Pressures pilot study.
    PLoS One. 2025;20:e0310758.
    PubMed         Abstract available

  19. ZHU L, Zhong L, Huang G
    Clinical efficacy and Safety of Baloxavir Marboxil compared with Oseltamivir against influenza virus in children: A systematic review and meta-analysis.
    PLoS One. 2025;20:e0326777.
    PubMed         Abstract available

  20. LUNDA O, Chauke L, Daef G, Olorunfemi G, et al
    Maternal deaths before and during COVID-19 pandemic: Causes and avoidable factors in a tertiary hospital in South Africa, 2018?2022.
    PLoS One. 2025;20:e0326424.
    PubMed         Abstract available

  21. MURPHY J, Livings MS, Wong M, Huang J, et al
    The association between community solidarity and adoption of public health preventive measures during the COVID-19 pandemic in a cross-sectional, multi-national sample.
    PLoS One. 2025;20:e0324234.
    PubMed         Abstract available

  22. VALLEE G, Xi D, Avramovic G, O'Kelly B, et al
    Evaluating the longitudinal physical and psychological health effects of persistent long Covid 3.5 years after infection.
    PLoS One. 2025;20:e0326790.
    PubMed         Abstract available

  23. ZEBARDAST A, Sadeghi K, Nejati A, Zadheidar S, et al
    A targeted approach for multiplex detection of respiratory viruses in cases with severe acute respiratory infections by nanopore sequencing.
    PLoS One. 2025;20:e0324601.
    PubMed         Abstract available

  24. MANCHEL A, Erdemir A, Mulugeta L, Ku JP, et al
    A rubric for assessing conformance to the Ten Rules for credible practice of modeling and simulation in healthcare.
    PLoS One. 2025;20:e0313711.
    PubMed         Abstract available

  25. DEMIRKIRAN B, Isin A, Sungur Y, Melekoglu T, et al
    The impact of 8-week re-training following a 14-week period of training cessation on Greco-Roman Wrestlers.
    PLoS One. 2025;20:e0326731.
    PubMed         Abstract available

  26. AMELINE AS, Chandra DN, Htet MK, Zahra NL, et al
    Prevalence and factors associated with anemia among pregnant women during the COVID-19 pandemic in East Lombok district, Indonesia.
    PLoS One. 2025;20:e0323942.
    PubMed         Abstract available

  27. AQEEL I, Majid A, Alahmadi TJ, Althubaity A, et al
    In-silico study of approved drugs as potential inhibitors against 3CLpro and other viral proteins of CoVID-19.
    PLoS One. 2025;20:e0325707.
    PubMed         Abstract available

  28. WHARTON E, O'Brien T, Foster RJ, Giebel C, et al
    "I don't know if it makes a difference to safety?" perception vs actuality: A mixed-methods study on older adults' experiences of home stair falls revealed during COVID-19 lockdown.
    PLoS One. 2025;20:e0326850.
    PubMed         Abstract available

  29. AUNG KT, Htun YM, Htet ZL, Soe YNM, et al
    Parental hesitancy on COVID-19 vaccination of children under the age of 16: A cross-sectional mixed-methods study among factory workers.
    PLoS One. 2025;20:e0327056.
    PubMed         Abstract available

  30. NGUYEN QT, Nguyen MPN, Bui NY, Ngo MQ, et al
    The complex interplay of personal and external factors in medical students' specialty decision-making: A qualitative study.
    PLoS One. 2025;20:e0326932.
    PubMed         Abstract available

  31. OLARTE L, Lee B, Banerjee D, Swanson DS, et al
    Pneumococcal colonization dynamics among young children with and without respiratory symptoms during the first year of the SARS-CoV-2 pandemic.
    PLoS One. 2025;20:e0327046.
    PubMed         Abstract available

  32. JEONG JY, Jeong YM
    Health behavior and mental health by gender in Korean adults before, during, and after the COVID-19 pandemic.
    PLoS One. 2025;20:e0325895.
    PubMed         Abstract available

  33. BEKUMA TT, Seme A, Ahmed S, Abera M, et al
    Level and determinants of pentavalent vaccine dropout during infancy: A hierarchical analysis of community-level longitudinal study.
    PLoS One. 2025;20:e0326684.
    PubMed         Abstract available

  34. VERLY-MIGUEL M, Lopes CS, Freitas JV, Garcia MC, et al
    Depression, anxiety and change in eating habits during the COVID-19 pandemic in Brazilian university students.
    PLoS One. 2025;20:e0326856.
    PubMed         Abstract available

  35. AL SUFIAN SHUVO A, Maekawa Y, Kassai M, Kawahara T, et al
    Inhibitory effects of a hot-water extract of cumin fruit on influenza A virus infection.
    PLoS One. 2025;20:e0326423.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  36. JURASZEK J, Kadam RU, Branduardi D, van Ameijde J, et al
    De novo design of D-peptide ligands: Application to influenza virus hemagglutinin.
    Proc Natl Acad Sci U S A. 2025;122:e2426554122.
    PubMed         Abstract available

  37. GUTMANN T, Kuster D, Hyman AA
    SARS-CoV-2 nucleocapsid protein directly prevents cGAS-DNA recognition through competitive binding.
    Proc Natl Acad Sci U S A. 2025;122:e2426204122.
    PubMed         Abstract available


    Vaccine

  38. SONG Z, Ma Y, Jiao L, Yu R, et al
    Lovastatin enhanced immune response to avian influenza vaccine in chickens and changed mRNA expression in the bursa of fabricius.
    Vaccine. 2025;61:127438.
    PubMed         Abstract available

  39. SHINJOH M, Tamura K, Yamaguchi Y, Fukushima H, et al
    Influenza vaccination in Japanese children, 2024/25: Effectiveness of inactivated vaccine and limited use of newly introduced live-attenuated vaccine.
    Vaccine. 2025;61:127429.
    PubMed         Abstract available

  40. SAMY A, Alber A, Fife M, Hammond JA, et al
    IFITM knockout DF1 cells produce higher influenza and newcastle disease viral yields: a proof of concept for avian origin cell-based vaccine production.
    Vaccine. 2025;61:127360.
    PubMed         Abstract available

  41. MISHINA M, Cao W, Ende Z, Sharma SS, et al
    Recombinant quadrivalent influenza vaccine (RIV) induces robust cell-mediated and HA-specific B cell humoral immune responses among healthcare personnel.
    Vaccine. 2025;61:127361.
    PubMed         Abstract available


    Virology

  42. BRUNO A, de Mora D, Olmedo M, Garces J, et al
    Highly pathogenic avian influenza A (H5N1) virus outbreaks in South America in 2022-2024: a comprehensive review of an ongoing panzootic.
    Virology. 2025;610:110602.
    PubMed         Abstract available

  43. NGUYEN XD, Le B, Yang Q, Wang B, et al
    PathoSift Pro: A novel size-based bioaerosol sampler for effectively detecting infectious airborne influenza virus.
    Virology. 2025;610:110609.
    PubMed         Abstract available

  44. PASQUALE S, Moscara L, Palmieri C, Martinelli A, et al
    Safety of SARS-CoV-2 XBB.1.5 and seasonal influenza vaccines co-administration: data from a perspective observational active surveillance study. Puglia (Italy), season 2023/2024.
    Virology. 2025;610:110613.
    PubMed         Abstract available

Highly Pathogenic Avian #Influenza Virus A #H5N1 subclade 2.3.4.4 b isolated from a European grey #seal (Halichoerus grypus) is highly virulent in #ferrets

 


Abstract

Highly pathogenic avian influenza A viruses subtype H5N1 (HPAIV H5N1), subclade 2.3.4.4b infect multiple avian and mammalian species, posing a potential pandemic risk. Here we describe the outcomes of infection of ferrets with a HPAIV H5N1 virus, isolated from a European grey seal in 2023, compared with an older HPAIV H5N1 (A/Indonesia/05/2005). Overall, infection of ferrets with A/grey seal/Netherlands/302603/2023 caused more rapid mortality than infection of ferrets with A/Indonesia/05/2005. Animals developed severe pneumonia and irreversible hypothermia, associated with high levels of virus replication and histopathological changes in the respiratory tract and peripheral organs. As animal models for severe avian influenza virus infections in humans play a key role in the development of intervention strategies against these infections, these findings highlight the importance of using updated ferret models based on circulating virus strains.

Source: Journal of Infectious Diseases, https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaf348/8176868

____

Friday, June 27, 2025

Seventh #Update on #Developments in #Iran (#War) (#IAEA, June 27 '25)

 


Radiation levels in the Gulf region remain normal following the 12-day conflict that severely damaged several nuclear facilities in Iran, Director General Rafael Mariano Grossi of the International Atomic Energy Agency (IAEA) said today.

Citing regional data reported regularly to the IAEA through the International Radiation Monitoring System (IRMIS), Director General Grossi noted that this 48-nation network would have detected an important radioactive release from any damaged nuclear power reactor.

“From a nuclear safety perspective, Iran’s Bushehr Nuclear Power Plant and the Tehran Research Reactor represented our main concern as any strike affecting those facilities – including their off-site power lines – could have caused a radiological accident with potential consequences in Iran as well as beyond its borders in the case of the Bushehr plant. It did not happen, and the worst nuclear safety scenario was thereby avoided,” Director General Grossi said.

Stressing again that nuclear facilities should never be attacked, he reiterated the IAEA’s current assessment – based on information received from Iran’s Nuclear Regulatory Authority – that this month’s Israeli and U.S. strikes on Iranian nuclear sites would have caused localized radioactive releases inside the impacted facilities and localized toxic effects, but there has been no report of increased off-site radiation levels.

The Director General also emphasised the need for IAEA inspectors to continue their verification activities in Iran, as required under its Comprehensive Safeguards Agreement (CSA) with the Agency.

Source: International Atomic Energy Agency, https://www.iaea.org/newscenter/pressreleases/update-on-developments-in-iran-7

____

Production and Immune Response Against #Pandemic #Influenza Candidate #Vaccines as Preparedness Against the Circulating #H5N1 Influenza Viruses

Abstract

Background/Objectives:

H5N1 influenza viruses are spreading worldwide and threaten global public health. Preparedness is necessary to mitigate the worst-case scenario should an H5N1 influenza pandemic occur and justify the development of vaccines against circulating H5N1 viruses of concern. 

Methods

The production and characterization of egg-based split and inactivated H5Nx of three distinct monovalent antigens from clades 2.3.4.4b, 2.3.2.1c, and 2.3.4 were performed at an industrial scale. These antigens were formulated and their immune responses, when combined or not with IB160 squalene-based oil-in-water emulsion adjuvant in a rat model, were evaluated in a one- or two-dose immunization schedule. IgG antibodies, hemagglutination inhibitions, and microneutralization titers were measured for vaccine-induced immunity and cross-reactivity. 

Results

Three monovalent vaccines from clades 2.3.4.4b, 2.3.2.1c, and 2.3.4 were produced at an industrial scale and characterized. The immune responses against the monovalent vaccines showed a clade-specific antibody response and the need to combine with IB160 adjuvant for a required immune response. 

Conclusions

Considering the candidate vaccine viruses (CVVs) with the testing potency reagents available and that the antibody response obtained against the CVVs produced was clade-specific, IDCDC RG-71A is the indicated CVV for the predominant currently circulating H5N1 influenza virus of clade 2.3.4.4b and must be combined with adjuvant to induce a higher and efficacious immune response in a two-dose immunization protocol.

Source: Vaccines (Basel), https://www.mdpi.com/2076-393X/13/6/620

____

#Mpox, Multi-country external #situation #report no. 54 published 27 June (#WHO)



{Summary)

KEY FIGURES 

{Area - Number of reported confirmed cases - Number of deaths among confirmed cases - Number of reporting countries}

-- Global (1 Jan – 31 May 2025)* - 24 672 - 82 - 75 

Key countries (01 Jan – 22 June 2025)

- Democratic Republic of the Congo - 12 208 - 22 - ...

- Uganda - 5636 - 31  - ...

- Sierra Leone - 4294 - 28 - ...

- Burundi - 1079 - 0 - ...

{*} Most recent global surveillance data available.


Highlights

In May 2025, a total of 6823 confirmed mpox cases and 16 deaths (Case Fatality Ratio: 0.2%) were reported from 49 countries across all WHO regions.

The majority of mpox cases continue to be reported from the WHO African Region, with 18 countries currently experiencing active ongoing transmission.

Since the last report, Ethiopia and Italy have reported their first cases of mpox due to clade Ib monkeypox virus (MPXV). In addition, North Macedonia, the Republic of the Congo, and Togo have reported their first cases of mpox clade IIb MPXV. Albania has reported its first mpox case, and genomic sequencing analysis is underway to determine the clade.

Community transmission of clade Ib MPXV remains limited to countries in Central and East Africa.

In Sierra Leone, the epidemic trend is consistently declining, although recent data should be interpreted with caution due to reporting delays.

Eleven African countries have received mpox vaccines, of which seven have started mpox vaccination. More than 731 000 doses of the MVA-BN vaccine have been administered to date.

WHO has updated its guideline on clinical management and infection prevention and control for mpox.

The WHO Director-General determined that the ongoing upsurge of mpox continues to constitute a public health emergency of international concern (PHEIC), following the fourth meeting of the International Health Regulations (IHR) Emergency Committee on 5 June 2025.

(...)

Source: World Health Organization, https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report--54---27-june-2025

____

#Evolution of #antibody cross-reactivity to #influenza #H5N1 #neuraminidase from an N2-specific germline

Abstract

The ongoing spread of highly pathogenic avian influenza H5N1 clade 2.3.4.4b virus in animals and occasional spillover to humans have raised concerns about a potential H5N1 pandemic. Although recent studies have shown that pre-existing human antibodies can recognize H5N1 neuraminidase, there is a lack of molecular understanding of how this cross-reactivity develops. Using a phage display antibody library derived from 245 healthy donors, this study isolates an antibody, known as HB420, that cross-reacts with the neuraminidases of human H3N2 and avian H5N1 clade 2.3.4.4b viruses and confers protection in vivo. Cryo-EM analysis shows that HB420 targets the neuraminidase active site by mimicking sialic acid binding through a single Asp residue. Additionally, the inferred germline of HB420 is N2-specific but acquires cross-reactivity to H5N1 neuraminidase through somatic hypermutations. Overall, our findings provide insights into how neuraminidase antibody evolves breadth, which has important implications for the development of broadly protective influenza vaccines.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.06.20.660733v1

____

#USA, Monitoring for Avian #Influenza A(#H5) Virus In #Wastewater (US CDC, June 27 '25)

 


{Excerpts}

Time Period: June 15, 2025 - June 21, 2025

- H5 Detection3 sites (0.8%)

- No Detection367 sites (99.2%)

- No samples in last week55 sites




(...)

Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/bird-flu/h5-monitoring/index.html

____

#Global #update on susceptibilities of #influenza viruses to #neuraminidase #inhibitors and the cap-dependent endonuclease inhibitor #baloxavir, 2020–2023

Highlights

• Antiviral susceptibility to NA inhibitors and PA inhibitor baloxavir was determined for seasonal and zoonotic influenza viruses circulating globally during 2020–2023.

• Low global frequencies (0.1-0.2%) of seasonal influenza viruses with reduced or highly reduced inhibition by NAI inhibitors were observed as in previous years.

• Low global frequencies of seasonal influenza viruses (∼ 0.1%) with reduced susceptibility to baloxavir were observed, with the rate in Japan elevated (3.3%) in 2022–2023, as has been seen previously.

• For zoonotic viruses, 2.7% contained genetic markers associated with reduced or highly reduced inhibition to NA inhibitors and none contained markers associated with reduced susceptibility for baloxavir.

• For the treatment of influenza, NA inhibitors and baloxavir remain suitable.


ABSTRACT

Antiviral susceptibility of influenza viruses is monitored by the World Health Organization Global Influenza Surveillance and Response System. This study describes a global analysis of the susceptibility of influenza viruses to neuraminidase (NA) inhibitors (NAIs, oseltamivir, zanamivir, peramivir, laninamivir) and the cap-dependent endonuclease inhibitor (CENI, baloxavir) for three periods (May to May for 2020–2021, 2021–2022 and 2022–2023). In particular, global influenza activity declined significantly in 2020-2021 and 2021-2022 when compared to the pre-pandemic period of COVID-19. Combined phenotypic and NA sequence-based analysis revealed that the global frequency of seasonal influenza viruses with reduced or highly reduced inhibition (RI/HRI) by NAIs remained low, 0.09% (2/2224), 0.12% (27/23465) and 0.23% (124/53917) for 2020–2021, 2021–2022 and 2022–2023, respectively. As in previous years, NA-H275Y in A(H1N1)pdm09 viruses was the most frequent substitution causing HRI by oseltamivir and peramivir. Sequence-based analysis of polymerase acidic (PA) protein supplemented with phenotypic testing revealed low global frequencies of seasonal influenza viruses with reduced susceptibility (RS) to baloxavir, 0.07% (1/1376), 0.05% (9/18380) and 0.12% (48/39945) for 2020–2021, 2021–2022 and 2022–2023, respectively; commonly associated substitutions were PA-I38T/M/L. In Japan, the rate was 3.3% (16/488) during 2022–2023, with 11 A(H3N2) viruses having PA-I38T/M substitutions. For zoonotic viruses, 2.7% (3/111) contained substitutions, one each NA-H275Y, NA-S247N and NA-N295S, associated with RI/HRI NAI phenotypes, and none contained PA substitutions associated with RS to baloxavir. In conclusion, the great majority of seasonal and zoonotic influenza viruses remained susceptible to NAIs and CENI baloxavir.

Source: Antiviral Research, https://www.sciencedirect.com/science/article/abs/pii/S0166354225001433?via%3Dihub

____

Thursday, June 26, 2025

#Mycoplasma pneumoniae #Infections in Hospitalized #Children — #USA, 2018–2024

Summary

- What is already known about this topic?

-- Mycoplasma pneumoniae is a common cause of community-acquired pneumonia (CAP) in school-aged children. In the United States, M. pneumoniae infection prevalence decreased during the COVID-19 pandemic and remained low through 2023.

- What is added by this report?

-- The number of hospital discharges of children with M. pneumoniae–associated CAP from U.S. pediatric hospitals increased sharply in 2024, accounting for approximately one half of hospitalized children with CAP. This number included children aged <5 years, a group in which M. pneumoniae infections have historically been less commonly reported. Data on length of hospitalization and intensive care unit admissions indicate that M. pneumoniae infections in 2024 were not more severe than 2018–2023 infections.

- What are the implications for public health practice?

-- Increased awareness among health care providers might improve diagnosis and could guide treatment of M. pneumoniae infections among children of all ages, especially during periodic increases in M. pneumoniae circulation and among children requiring hospitalization.


Abstract

Mycoplasma pneumoniae is a common bacterial cause of respiratory infection and a leading cause of childhood community-acquired pneumonia (CAP). Increases in M. pneumoniae infection occur every 3–5 years. In the United States, M. pneumoniae prevalence decreased during and immediately after the COVID-19 pandemic. Information from 42 U.S. children’s hospitals that provided information to the Pediatric Health Information System, a database of clinical and resource use information, was used to identify discharge diagnostic codes for 2018–2024 indicating M. pneumoniae infection. M. pneumoniae–associated CAP incidence among children aged ≤18 years was significantly higher in 2024 (12.5 per 1,000 hospitalizations) than during 2018–2023 (2.1). During the study period, an M. pneumoniae diagnostic code was listed in 11.5% of pediatric CAP hospitalizations, peaking at 53.8% in July 2024. Among pediatric M. pneumoniae CAP cases, the highest percentage occurred among children aged 6–12 years (42.6%), followed by children aged 2–5 years (25.7%) and 13–18 years (21.1%). The lowest occurred among those aged 12–23 months (6.4%) and 0–11 months (4.2%). M. pneumoniae infections in 2024 were not more severe than 2018–2023 infections, as assessed by length of hospitalization and percentage of patients admitted to an intensive care unit. The increase in M. pneumoniae infections in the United States in 2024 might be higher than previous periodic increases because the susceptible population was larger after sustained low incidence during and immediately after the COVID-19 pandemic. Health care providers should be aware of the periodicity of M. pneumoniae CAP and consider testing for this pathogen as a cause of respiratory illness among children of all ages.

Source: US Centers for Disease Control and Prevention, MMWR, https://www.cdc.gov/mmwr/volumes/74/wr/mm7423a1.htm?s_cid=mm7423a1_e&ACSTrackingID=USCDC_921-DM147954&ACSTrackingLabel=Week%20in%20MMWR%3A%20Vol.%2074%2C%20June%2026%2C%202025&deliveryName=USCDC_921-DM147954

____

#UK {#Wales} - High pathogenicity avian #influenza #H5N1 viruses (#poultry) (Inf. with) - Immediate notification



{Pembrokeshire, Wales} A backyard flock of 120 laying hens. Increased mortality and other clinical signs consistent with avian influenza (AI) were reported. Samples were collected and tested positive for highly pathogenic avian influenza (HPAI) H5N1.

Source: WOAH, https://wahis.woah.org/#/in-review/6579

____

Wednesday, June 25, 2025

Highly Pathogenic Avian #Influenza A(#H5N1) Virus: How Far Are We from a New #Pandemic?

Simple Summary

The present commentary deals with the pandemic risk brought about by the highly pathogenic avian influenza (HPAI) A(H5N1) virus. Such a pandemic alarm is justified, among others, by the progressively and rapidly expanding range of virus-susceptible hosts, including humans alongside a significant number of domestic and wild avian and mammalian species, several of which appear to be geographically and phylogenetically distant from each other. Despite its well-established zoonotic potential, no clear-cut evidence of a sustained and efficient HPAI A(H5N1) virus interhuman transmission has thus far been reported. Should this happen in a more or less near future, it could pave the way for a new pandemic. Based upon the above, a “One Health, One Earth, One Ocean”-focused, holistic approach would be the necessary prerequisite to deal in an appropriate way with the HPAI A(H5N1) virus-associated zoonotic and pandemic risk.


Abstract

The focus of this commentary is represented by the pandemic risk associated with the highly pathogenic avian influenza (HPAI) A(H5N1) virus, clade 2.3.4.4b. More in detail, the herein dealt pandemic alarm appears to be primarily justified by the huge and progressively growing number of virus-susceptible domestic and wild birds and mammals, including threatened marine mammal species like South American sea lions and elephant seals as well as harbour porpoises, bottlenose dolphins and polar bears. Of major concern is the susceptibility of dairy cattle to HPAI A(H5N1) virus, particularly the documented and unprecedented colonization of host’s mammary gland tissue, resulting in viral shedding through the milk alongside a large series of cases of infection in dairy farm workers in several USA locations. Despite well-documented zoonotic capability, no evidences of a sustained and efficient HPAI A(H5N1) viral transmission between people have been hitherto reported. If this were to happen sooner or later, a new pandemic might consequently arise. Therefore, keeping all this in mind and based upon the lessons taught by the COVID-19 pandemic, a “One Health, One Earth, One Ocean”-centered approach would be absolutely needed in order to deal in the most appropriate way with the HPAI A(H5N1) virus-associated zoonotic and pandemic risk.

Source: Veterinary Sciences, https://www.mdpi.com/2306-7381/12/6/566

____

#Denmark - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification


Credit: Wikipedia. By Bengt Nyman from Vaxholm, Sweden - Larus canus 2203, CC BY 2.0, https://commons.wikimedia.org/w/index.php?curid=49877446

___

On the 16th of January 2025, a herring gull was found dead near a wildlife care station. The gull was received at National Reference Laboratory on the 13th of May 2025, and samples from the bird tested positive for HPAI H5N1 on the 20th of June 2025.

Source: WOAH, https://wahis.woah.org/#/in-review/6574

____

Metabolomic Profiling of #Plasma Reveals Differential #Disease Severity #Markers in avian #influenza A(#H7N9) infection Patients

Highlights

• The characteristics of plasma metabolome in H7N9 patients were first revealed.

• It was discovered that lipid-like molecules were downregulated in death group.

• Metabolites of the tryptophan metabolic pathway were elevated in death group.

• The metabolite-based machine learning achieved an AUC of 0.929 on the test set.


Abstract

Objectives

Avian influenza such as H7N9 is currently a major global public health risk, and at present, there is a lack of relevant diagnostic and treatment markers.

Methods

We collected plasma samples from 104 confirmed H7N9 patients, 31 of whom died. Plasma metabolites were detected by UHPLC-HRMS, and a survival prediction model based on metabolites was constructed by machine learning models.

Results

A total of 1536 metabolites were identified in the plasma samples of H7N9 patients, of which 64 metabolites were up-regulated and 35 metabolites were down-regulated in the death group. The enrichment analysis of Tryptophan metabolism, Porphyrin metabolism and Riboflavin metabolism were significantly up-regulated in the death group. We found that most Lipids and lipid−like molecules were down-regulated in the death group, and Organoheterocyclic compounds were significantly up-regulated in the death group. A machine learning model was constructed for predicting mortality based on Porphobilinogen, 5-Hydroxyindole-3-acetic acid, L-Kynurenine, Biliverdin, and D-Dimer. The AUC on the test set was 0.929.

Conclusions

We first revealed the plasma metabolomic characteristics of H7N9 patients and found that a machine learning model based on plasma metabolites could predict the risk of death for H7N9 in the early stage of admission.

Source: International Journal of Infectious Diseases, https://www.ijidonline.com/article/S1201-9712(25)00181-X/fulltext

____

Infectome analysis of #bat #kidneys from #Yunnan province, #China, reveals novel #henipaviruses related to #Hendra and #Nipah viruses and prevalent bacterial and eukaryotic microbes

Abstract

Bats are natural reservoirs for a wide range of microorganisms, including many notable zoonotic pathogens. However, the composition of the infectome (i.e., the collection of viral, bacterial and eukaryotic microorganisms) within bat kidneys remains poorly understood. To address this gap, we performed meta-transcriptomic sequencing on kidney tissues from 142 bats, spanning ten species sampled at five locations in Yunnan province, China. This analysis identified 22 viral species, including 20 novel viruses, two of which represented newly discovered henipaviruses closely related to the highly pathogenic Hendra and Nipah viruses. These henipaviruses were found in the kidneys of bats inhabiting an orchard near villages, raising concerns about potential fruit contamination via bat urine and transmission risks to livestock or humans. Additionally, we identified a novel protozoan parasite, tentatively named Klossiella yunnanensis, along with two highly abundant bacterial species, one of which is a newly discovered species—Flavobacterium yunnanensis. These findings broaden our understanding of the bat kidney infectome, underscore critical zoonotic threats, and highlight the need for comprehensive, full-spectrum microbial analyses of previously understudied organs to better assess spillover risks from bat populations.


Author summary

Although extensive investigations have been conducted on the bat virome, most studies have focused on fecal samples, leaving other tissues, such as the kidney, largely unexplored. However, the kidney can harbor important zoonotic pathogens, including the highly pathogenic Hendra and Nipah viruses, and genomic evidence of henipaviruses in bats from China has remained undocumented. In this study, we report the first detection of two novel henipavirus genomes from bat kidneys in China, one of which is the closest known relative of pathogenic henipaviruses identified to date. Beyond virome analysis, our study also examined highly prevalent bacteria and eukaryotic microbes, identifying those potentially relevant to bat infections. Overall, these findings provide valuable insights into the infectome of the bat kidney, highlighting the need for broader microbial surveillance beyond the gastrointestinal tract.

Source: PLoS Pathogens, https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1013235

____

Tuesday, June 24, 2025

#Investigation of #human #infection with #H5N6 avian #influenza cases in #Sichuan from 2014-24: a retrospective study

Abstract

Objective

The objective is to examine the epidemiology and clinical features of human cases infected with H5N6 avian influenza in Sichuan Province from 2014 to 2024, and to offer guidance for the prevention and management of human infections with H5N6 avian influenza.

Methods

Epidemiological survey reports of H5N6 avian influenza cases in Sichuan Province from 2014 to 2024 were compiled, and the epidemiological context and characteristics of 16 human cases infected with H5N6 avian influenza in the province were summarized and analyzed using descriptive epidemiological methods.

Results

From 2014, when the initial human case of H5N6 infection was documented in Sichuan Province, to 2024, there have been 16 human cases of H5N6 avian influenza in the region, resulting in 12 fatalities and a case fatality rate of 75%. The instances were predominantly located in the Chengdu Plain, eastern Sichuan, and southern Sichuan.

Conclusion

Human instances of H5N6 avian influenza in Sichuan Province exhibit no discernible periodicity, and entail significant fatality rates. It is essential to enhance the early diagnosis and treatment of avian influenza cases in medical facilities, prioritize farmers with preexisting conditions who have been in contact with deceased poultry, conduct influenza virus testing promptly, and administer antiviral medications at the earliest opportunity. Simultaneously, we must effectively engage in public awareness and education for the populace, manage poultry scientifically, and prevent direct contact with deceased poultries.

Source: Frontiers in Public Health, https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1603158/full

____

Sixth #Update on #Developments in #Iran (#War) (#IAEA, June 24 '25)

 


Director General Rafael Mariano Grossi has welcomed today’s announcements regarding the situation in Iran and stressed the need for a resumption of the IAEA’s indispensable safeguards verification work in the country following a 12-day military conflict that severely damaged several of its nuclear sites.

In a letter to Iranian Foreign Minister Dr Abbas Araghchi, Director General Grossi also proposed that they meet soon.

“Resuming cooperation with the IAEA is key to a successful diplomatic agreement to finally resolve the dispute over Iran’s nuclear activities. I’ve written to Foreign Minister Araghchi stressing the importance of us working together and proposing to meet soon,” he said.

IAEA inspectors have remained in Iran throughout the conflict and are ready to start working as soon as possible, going back to the country’s nuclear sites and verifying the inventories of nuclear material – including more than 400 kg of uranium enriched to 60% - which they last verified a few days before the Israeli air strikes began on 13 June.

Even though the conflict interrupted safeguards inspections in the country, the IAEA has been closely monitoring the impact of the military strikes on Iranian nuclear sites at Arak, Esfahan, Fordow and Natanz as well as the possible consequences for human health and the environment, based on relevant information received from Iran’s Nuclear Regulatory Authority.

“As I have repeatedly stated – before and during the conflict – nuclear facilities should never be attacked due to the very real risk of a serious radiological accident,” Director General Grossi said.

“During these attacks, we have seen extensive damage at several nuclear sites in Iran, including its uranium conversion and enrichment facilities. Our assessment is that there has been some localized radioactive as well as chemical release inside the affected facilities that contained nuclear material – mainly uranium enriched to varying degrees – but there has been no report of increased off-site radiation levels,” he said.  

Still, the IAEA is aware of concerns in the region regarding any radiological consequences as a result of the strikes on nuclear facilities.

“Based on the data available to us, the IAEA can provide assurances that there has been no radiological impact to the population and the environment in neighbouring countries. Crucially in terms of nuclear safety, Iran’s research and power reactors were not targeted,” Director General Grossi said.

In addition to the detailed assessment that Director General Grossi provided to the IAEA Board of Governors on Monday, the IAEA has identified additional impact points at nuclear sites at Fordow and Natanz as a result of strikes carried out before today’s announcements on the situation in Iran.

Regarding the additional strikes to Fordow that were reported early on Monday – after the U.S. bombing of the facility early on Sunday – the IAEA assesses that access roads close to the underground facility and one of its entrances were hit.

At Natanz, the IAEA has identified two impact holes from the U.S. strikes above the underground halls that had been used for enrichment as well as for storage. Based on its knowledge of what these halls contained, the IAEA assesses that this strike may have caused localized contamination and chemical hazards.

Source: International Atomic Energy Agency, https://www.iaea.org/newscenter/pressreleases/update-on-developments-in-iran-6

____

#China reported three new #human cases of #infection with #H9N2 #influenza and one case of #H10N3 virus (#HK CHP, June 24 '25)



{Excerpt}

Epi-Week 25 2025

Avian influenza A(H9N2)

- Henan Province

-- 1) A 52-year-old woman with onset on May 10, 2025. 

- Hunan Province

-- 2) A 72-year-old woman with onset on May 14, 2025. 

- Sichuan Province

--3) A six-year-old boy with onset on May 14, 2025.

Avian influenza A(H10N3)

- Shaanxi Province

-- 1) A 70-year-old woman with onset on April 21, 2025. 

(...)

Source: Centre for Health Protection, Hong Kong PRC SAR, https://www.chp.gov.hk/files/pdf/2025_avian_influenza_report_vol21_wk25.pdf

____

My New Space

Most Popular Posts